Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06712836
PHASE2

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

Sponsor: Metsera, a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.

Official title: A Phase 2b, Multi-Center, Randomized, Placebo-Controlled Double-Blind Study to Investigate the Safety and Efficacy of Once-Weekly MET097 in Participants With Obesity and Overweight (VESPER-1)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

225

Start Date

2024-10-24

Completion Date

2026-05

Last Updated

2026-02-17

Healthy Volunteers

No

Interventions

DRUG

MET097

MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.

DRUG

Placebo

Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

Locations (2)

Research Site MET097 24-201-001

Anaheim, California, United States

Research Site MET097 24-201-002

Hollywood, Florida, United States